利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.021 秒)

    Method for purification of complement factor H
    1.
    发明授权
    Method for purification of complement factor H 有权
    纯化补体因子H的方法

    公开(公告)号：US08809510B2

    公开(公告)日：2014-08-19

    申请号：US13879283

    申请日：2011-10-13

    申请人： Hubert Brandstaetter ,  Petra Schulz ,  Juergen Roemisch

    发明人： Hubert Brandstaetter ,  Petra Schulz ,  Juergen Roemisch

    IPC分类号： C07K1/18 ,  A61K38/00 ,  G01N30/02 ,  C07K1/22 ,  C07K1/36 ,  A61K39/00 ,  C07K14/705 ,  A61K35/16 ,  C07K14/47

    CPC分类号： C07K14/472 ,  A61K38/1709 ,  C07K1/36 ,  C07K14/435 ,  C07K14/47

    摘要： A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a) providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b) performing a cation exchange chromatography in particular as first chromatographic step; c) performing an anion exchange chromatography; d) performing a hydroxyl apatite chromatography; e) followed by ultra/diafiltration to obtain a complement Factor H concentrate.

    摘要翻译： 用于从补体因子H纯化补体因子H的方法，所述补体因子H含有血液或血浆中的源，特别是含H因子的来源的辛酸盐沉淀物。 通过向血液或血浆的级分中加入辛酸盐离子获得，包括以下步骤：a）提供含有因子H的来源，特别是辛酸沉淀重构以提供补体因子H的溶液; b）特别是进行阳离子交换层析作为第一色谱步骤; c）进行阴离子交换层析; d）进行羟基磷灰石层析; e），然后进行超/渗滤以获得补体因子H浓缩物。

    METHOD FOR PURIFICATION OF COMPLEMENT FACTOR H
    2.
    发明申请
    METHOD FOR PURIFICATION OF COMPLEMENT FACTOR H 有权

    公开(公告)号：US20130203971A1

    公开(公告)日：2013-08-08

    申请号：US13879283

    申请日：2011-10-13

    申请人： Hubert Brandstaetter ,  Petra Schulz ,  Juergen Roemisch

    发明人： Hubert Brandstaetter ,  Petra Schulz ,  Juergen Roemisch

    IPC分类号： C07K1/36 ,  C07K14/435

    CPC分类号： C07K14/472 ,  A61K38/1709 ,  C07K1/36 ,  C07K14/435 ,  C07K14/47

    摘要： A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a) providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b) performing a cation exchange chromatography in particular as first chromatographic step; c) performing an anion exchange chromatography; d) performing a hydroxyl apatite chromatography; e) followed by ultra/diafiltration to obtain a complement Factor H concentrate.

    ASSAY AND METHOD FOR THE IDENTIFICATION OF INDIVIDUAL RESPONSIVENESS TO IMMUNOGLOBULIN THERAPY
    3.
    发明申请
    ASSAY AND METHOD FOR THE IDENTIFICATION OF INDIVIDUAL RESPONSIVENESS TO IMMUNOGLOBULIN THERAPY 审中-公开
    用于识别免疫球蛋白治疗的个体反应的测定和方法

    公开(公告)号：US20150211064A1

    公开(公告)日：2015-07-30

    申请号：US14114276

    申请日：2012-06-06

    申请人： Stefan Meuer ,  Thomas Geise ,  Christian Jacobi ,  Stefan Haag ,  Juergen Roemisch

    发明人： Stefan Meuer ,  Thomas Geise ,  Christian Jacobi ,  Stefan Haag ,  Juergen Roemisch

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156

    摘要： A method for determining the likelihood of response of an individual, suffering from a disease, towards immunoglobulin therapy has the steps of providing a sample containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individual; genotyping of at least one of the polynucleotides of an ADAMTS9-Intron; a KLHDC8A-Intron or of a flanking region of the CD14 gene, and awarding the value of 1 for the homozygous Single Nucleotide Polymorphism combinations, which suggests that the blood sample stems from a person which will not respond to immunoglobulin treatment, while awarding the value of 0 for SNP not meeting that criteria, which suggests that the blood sample stems from a person which will respond to immunoglobulin treatment.

    摘要翻译： 确定患有疾病的个体对免疫球蛋白治疗的反应可能性的方法具有以下步骤：提供含有个体的B和T淋巴细胞，天然杀伤细胞，不变T细胞和单核细胞的样品; 至少一种ADAMTS9-内含子的多核苷酸的基因分型; KLHDC8A-内含子或CD14基因的侧翼区域，并且为纯合的单核苷酸多态性组合赋予1值，这表明血液样品源于不对免疫球蛋白治疗反应的人，同时赋予该值 为0的SNP不符合该标准，这表明血液样本来源于将对免疫球蛋白治疗作出反应的人。

    Process for the preparation in pure form of the protease activating blood clotting VII, its proenzyme or a mixture of both proteins by means of affinity chromatography
    8.
    发明授权
    Process for the preparation in pure form of the protease activating blood clotting VII, its proenzyme or a mixture of both proteins by means of affinity chromatography 失效
    以纯形式的蛋白酶活化凝血因子，其酶原或两种蛋白质的混合物通过亲和色谱法制备的方法

    公开(公告)号：US06670455B1

    公开(公告)日：2003-12-30

    申请号：US09632974

    申请日：2000-08-04

    申请人： Juergen Roemisch ,  Annette Feussner ,  Hans-Arnold Stoehr

    发明人： Juergen Roemisch ,  Annette Feussner ,  Hans-Arnold Stoehr

    IPC分类号： A61K3514

    CPC分类号： B01D15/3804 ,  B01D15/1871 ,  B01D15/327 ,  B01D15/3809 ,  B01D15/3828 ,  C12N9/6424

    摘要： A process for the preparation in pure form of the protease activating blood clotting factor VII and/or its proenzyme by the use of a chromatography separation processes and/or fractional precipitation is described. The process used may include adsorption on calcium phosphate/hydroxyapatite, a hydrophobic matrix, a chelate matrix, a matrix on which heparin or a substance related to heparin, such as heparin sulfate or dextran sulfate, is immobilized, or a matrix that is coated with an immobilized monoclonal or polyclonal antibody directed against the protein to be isolated, or F(ab) or F(ab)2 fragments of antibodies directed against the protein to be isolated. A pharmaceutical preparation and a reagent are described which contain the said protease and/or its proenzyme.

    摘要翻译： 描述了通过使用色谱分离方法和/或分级沉淀以纯形式的蛋白酶活化凝血因子VII和/或其酶原制备方法。 所使用的方法可以包括对磷酸钙/羟基磷灰石的吸附，疏水基质，螯合物基质，其上固定有肝素或与肝素相关的物质如硫酸肝素或硫酸葡聚糖的基质，或涂覆有 针对待分离的蛋白质的固定化单克隆抗体或多克隆抗体，或针对要分离的蛋白质的F（ab）或F（ab）2抗体片段）。 描述了含有所述蛋白酶和/或其酶原的药物制剂和试剂。